Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors

Cancer Investigation

Volumn 29, Issue 9, 2011, Pages 599-607

  Zhou, Jing ^a   Brinckerhoff, Constance ^b   Lubert, Susan ^a   Yang, Kui ^c   Saini, Jasmine ^a   Hooke, Jeffrey ^d   Mural, Richard ^a   Shriver, Craig ^d   Somiari, Stella ^a  

^a WINDBER RESEARCH INSTITUTE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c Colorado Foundation for Medical Care ^*  (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Breast cancers; Cancer biomarkers; Detection diagnosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERSTITIAL COLLAGENASE; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENE EXPRESSION; GENE INSERTION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054848571     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.621915     Document Type: Article

References (54)

1. Menon B, SinghM, Singh K. Matrix metalloproteinases mediate beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes. Am J Physiol Cell Physiol 2005;289:C168-C176. (Pubitemid 40880837)
2. McCawley LJ,Wright J, LaFleur BJ, Crawford HC, Matrisian LM. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am J Pathol 2008;173:1528-1539.
3. Wang W, Pan H, Murray K, Jefferson BS, Li Y. Matrix metalloproteinase-1 promotes muscle cell migration and differentiation. Am J Pathol 2009;174:541-549.
4. Zeng ZZ, Yao H, Staszewski ED, Rockwood KF, Markwart SM, Fay KS, Spalding AC, Livant DL. Alpha(5)beta(1) integrin ligand PHSRN induces invasion and alpha(5) mRNA in endothelial cells to stimulate angiogenesis. Transl Oncol 2009;2:8-20.
5. Shan B, Morris CA, Zhuo Y, Shelby BD, Levy DR, Lasky JA. Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells. J Mol Cell Cardiol 2007;42:517-525. (Pubitemid 46357551)
6. Gonzalez Rodriguez I, Rivas del Fresno M, Gil Ugarteburu R, Gonzalez Arriaga P, Lopez Cima F, Fernandez Samoano A, Muruamendiaraz Fernandez V, Fernandez Garcia I, Perez-Carral JR, Tardon A. Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience. Arch Esp Urol 2010;63:119-124.
7. Szarvas T, Becker M, vom Dorp F, Gethmann C, Totsch M, Bankfalvi A, Schmid KW, Romics I, Rubben H, Ergun S. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 2010;101:1300-1308.
8. Yi YC, Chou PT, Chen LY, KuoWH, Ho ES, Han CP, Yang SF. Matrixmetalloproteinase-7 (MMP-7) polymorphismis a risk factor for endometrial cancer susceptibility. Clin Chem Lab Med 2010;48:337-344.
9. Kim YW, Ko YT, Kim NK, Chung HC, Min BS, Lee KY, Park JP, Kim H. A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scand J Gastroenterol 2010;45:217-225.
10. Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res 2010;70:792-801.
11. Li M, Xiao T, Zhang Y, Feng L, Lin D, Liu Y, Mao Y, Guo S, Han N, Di X, Zhang K, Cheng S, Gao Y. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer 2010;69:341-347.
12. LuukkaaH, KlemiP,Hirsimaki P, Vahlberg T, KivisaariA,Kahari VM, Grenman R. Matrix metalloproteinase (MMP)-7 in salivary gland cancer. Acta Oncol 2010;49:85-90.
13. LuukkaaH, KlemiP, Leivo I,MakitieAA, Irish J, GilbertR,Perez- Ordonez B, Hirsimaki P, Vahlberg T, Kivisaari A, Kahari VM, Grenman R. Expression ofmatrixmetalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer. Head Neck 2010;32:1019-1027.
14. Yeh YC, Sheu BS, ChengHC, Wang YL,YangHB, Wu JJ. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci 2010;55:1649-1657.
15. Scherf DB, Dally H, Muller P, Werle-Schneider G, Jager B, Edler L, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A. Single nucleotide polymorphisms inmatrixmetalloproteinase genes and lung cancer chemotherapy response and prognosis. Eur Respir J 2010;35:381-390.
16. Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol 2010 Dec;27(4):1246-1253. Epub 2009 Nov 24.
17. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-214.
18. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005;11:481-483. (Pubitemid 40685969)
19. Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J Surg Res 2008;146:104-109. (Pubitemid 351442936)
20. Tower GB, Coon CI, Brinckerhoff CE. The 2G single nucleotide polymorphism (SNP) in theMMP-1 promoter contributes to high levels of MMP-1 transcription inMCF-7/ADR breast cancer cells. Breast Cancer Res Treat 2003;82:75-82. (Pubitemid 37476007)
21. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5325. (Pubitemid 28551108)
22. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymph node metastasis in breast cancer. J Exp Clin Cancer Res 2004;23:121-125. (Pubitemid 38552606)
23. Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, Jones JL. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 2007;13:6673-6680. (Pubitemid 350206803)
24. McColgan P, Sharma P. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 2009;125:1473-1478.
25. Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS, Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer 2005;115:368-376. (Pubitemid 40663739)
26. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, Scorza R. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344-2346. (Pubitemid 32751634)
27. Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, Ragos V, Vylliotis A, Spyridonidou S, Tsigris C, Yannopoulos A, Tesseromatis C, Neukam FW, Patsouris E. Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphismwith increased risk for oral squamous cell carcinoma. Anticancer Res 2007;27:459-464. (Pubitemid 46363366)
28. O-charoenrat P, Leksrisakul P, Sangruchi S. A functional polymorphism in thematrixmetalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 2006;118:2548-2553.
29. Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, Ueyama Y, Shinozaki F, Yamashita H, Hinoda Y. Association ofmatrixmetalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett 2004;211:19-24. (Pubitemid 38759765)
30. Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y, Minaguchi T, Nakamura Y, Tokino T, Kudo R. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 2000;91:612-615. (Pubitemid 30453788)
31. Six L, Grimm C, Leodolter S, Tempfer C, Zeillinger R, Sliutz G, Speiser P, Reinthaller A, Hefler LA. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol 2006;100:506-510. (Pubitemid 43246866)
32. Birkedal-Hansen B, MooreWG, Taylor RE, Bhown AS, Birkedal- Hansen H. Monoclonal antibodies to human fibroblast procollagenase. Inhibition of enzymatic activity, affinity purification of the enzyme, and evidence for clustering of epitopes in the NH2-terminal end of the activated enzyme. Biochemistry 1988;27:6751-6758.
33. Windsor LJ, Birkedal-Hansen H, Birkedal-Hansen B, Engler JA. An internal cysteine plays a role in the maintenance of the latency of human fibroblast collagenase. Biochemistry 1991;30:641-647.
34. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, Mc- Shane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
35. Walch K, Nagele F, Zeillinger R, Vytiska-Binstorfer E, Huber JC, Hefler LA. A polymorphism in the matrix metalloproteinase-1gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. Fertil Steril 2005;83:1565-1567. (Pubitemid 40615844)
36. Zhou P, Du LF, Lv GQ, Yu XM, Gu YL, Li JP, Zhang C. Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011;127:813-818.
37. JohanssonN, Ala-aho R,UittoV,Grenman R, FusenigNE, Lopez- Otin C, Kahari VM. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 2000;113(Pt 2):227-235. (Pubitemid 30088968)
38. Reunanen N, Westermarck J, Hakkinen L, Holmstrom TH, Elo I, Eriksson JE, Kahari VM. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stressactivated protein kinase pathways. J Biol Chem 1998;273:5137-5145. (Pubitemid 28108675)
39. Park CH, Lee MJ, Ahn J, Kim S, Kim HH, Kim KH, Eun HC, Chung JH. Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop. J Invest Dermatol 2004;123:1012-1019. (Pubitemid 39586819)
40. Di Girolamo N, Coroneo MT, Wakefield D. UVB-elicited induction of MMP-1 expression in human ocular surface epithelial cells is mediated through the ERK1/2 MAPK-dependent pathway. Invest Ophthalmol Vis Sci 2003;44:4705-4714. (Pubitemid 37315282)
41. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006;95:65-72. (Pubitemid 43228082)
42. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
43. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-325. (Pubitemid 36929717)
44. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999;26:108-116. (Pubitemid 29411441)
45. Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor andHer2 can predict the prognosis of breast cancer. Tumori 2010;96:103-110.
46. ChoiYH, Ahn JH, KimSB, Jung KH,GongGY, KimMJ, Son BH, Ahn SH, KimWK. Tissuemicroarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictivemarker of poor prognosis.Ann Oncol 2009;20:1337-1343.
47. Bosc DG, Goueli BS, Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001;20:6215-6224. (Pubitemid 32964434)
48. Yang CH, Cristofanilli M. The role of p53mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future Oncol 2006;2:247-255.
49. Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer 2005;6:61-76. (Pubitemid 40872948)
50. Coradini D, Daidone MG. Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol 2004;16:49-55. (Pubitemid 38241542)
51. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855.
52. Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (Collagenase- 1) gene expression. J Biol Chem 1999;274:11535-11540.
53. Sun Y, Zeng XR,Wenger L, Firestein GS, Cheung HS. P53 downregulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 2004;92:258-269.
54. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognosticmolecularmarker in breast cancer. Breast Cancer Res 2004;6:R24-R30.